Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.

abstract：:A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotran...

journal_title：Clinical neuropharmacology

authors： Gomez-Mancilla B,Bédard PJ

更新日期：1993-10-01 00:00:00

abstract：:The description of multiple classes of opioid receptors has had a major impact on our understanding of the mechanisms of analgesia. Three major classes of opioid receptors have been defined: mu, kappa, and delta. The mu receptors have been further subclassified into two distinct subtypes (mu 1 and mu 2), as have the d...

journal_title：Clinical neuropharmacology

authors： Pasternak GW

更新日期：1993-02-01 00:00:00

abstract：:Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Long KD,Gaskins B,Mastropaolo J

更新日期：2006-11-01 00:00:00

abstract：:We investigated genetic polymorphism of the cytochrome P-450 CYP2D6 gene from white patients with idiopathic Parkinson's disease (IPD). The mutations of the CYP2D6 gene associated with the poor metabolizer (PM) phenotype of the debrisoquine/sparteine polymorphism were analyzed in DNA of 130 IPD patients by a polymeras...

journal_title：Clinical neuropharmacology

authors： Bordet R,Broly F,Destée A,Libersa C,Lafitte JJ

更新日期：1996-06-01 00:00:00

abstract：:Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

journal_title：Clinical neuropharmacology

authors： Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

更新日期：1995-08-01 00:00:00

abstract：:The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-3...

journal_title：Clinical neuropharmacology

authors： Bessler H,Karp L,Notti I,Apter A,Tyano S,Djaldetti M,Weizman R

更新日期：1993-06-01 00:00:00

abstract：:Various reactions to benzodiazepine withdrawal have been widely described. Among these, seizures have occasionally occurred on abrupt withdrawal. Our own experience of 48 cases of seizures suspected to have been caused by benzodiazepine withdrawal and reported to the Adverse Drug Reaction (ADR) Monitoring Center (1979...

journal_title：Clinical neuropharmacology

authors： Fialip J,Aumaitre O,Eschalier A,Maradeix B,Dordain G,Lavarenne J

更新日期：1987-12-01 00:00:00

abstract：:We report the case of a 76-year-old, right-handed woman with progressive primary freezing of gait. Despite several therapeutic strategies, she continued to worsen to the point that she became confined to a wheelchair. Treatment with selegiline in doses up to 20 mg/d led to marked improvement of the gait disorder. This...

journal_title：Clinical neuropharmacology

authors： Zúñiga C,Lester J,Cersósimo MG,Díaz S,Micheli FE

更新日期：2006-01-01 00:00:00

abstract：:The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...

journal_title：Clinical neuropharmacology

authors： Thomas A,Iacono D,Bonanni L,D'Andreamatteo G,Onofrj M

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:Serotonin syndrome is a potentially fatal complication that usually occurs in the combination use of several serotonergic agents. We presented a patient with major depressive disorder under the treatment of bupropion, trazodone, and quetiapine. Serotonin syndrome developed soon after she received the first s...

journal_title：Clinical neuropharmacology

authors： Cheng YC,Liang CM,Liu HC

更新日期：2015-05-01 00:00:00

abstract：:The effects of 5-HT are varied and widely distributed throughout the human body. At this time, 5-HT research is a field ripe for "plucking." Not only is there a great demand for more selective agonists and antagonists, but there is more than enough work needed in receptor binding studies to keep pharmacologists employ...

journal_title：Clinical neuropharmacology

authors： Bonate PL

更新日期：1991-02-01 00:00:00

abstract：:The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...

journal_title：Clinical neuropharmacology

authors： Jorga KM,Davis TL,Kurth MC,Saint-Hilaire MH,LeWitt PA,Fotteler B,Zürcher G,Rabbia M

更新日期：2000-03-01 00:00:00

abstract：:Parkinson disease (PD) is a progressive, disabling, neurodegenerative disorder characterized by both motor and nonmotor symptoms. Monoamine oxidase B inhibitors, dopamine agonists, N-methyl-D-aspartate antagonists and levodopa (LD), with its various formulations and administration modes, mainly improve the motor sympt...

journal_title：Clinical neuropharmacology

authors： Müller T

更新日期：2013-05-01 00:00:00

abstract：:Clozapine is known to be beneficial for the treatment of dopamine agonist-induced psychotic states in patients with Parkinson's disease (PD). Many reports have suggested that it may also be efficacious for the treatment of parkinsonian tremor. We describe a patient with schizophrenia in whom early-onset PD appeared af...

journal_title：Clinical neuropharmacology

authors： Orr G,Munitz H,Hermesh H

更新日期：2001-03-01 00:00:00

abstract：BACKGROUND:Catatonia is a severe condition in patients. Electroconvulsive treatment or medication with benzodiazepines and/or antipsychotics are regarded as standard treatment. CASE PRESENTATION:We report a case of a patient with catatonic features in whom electroconvulsive treatment and benzodiazepine and/or antipsyc...

journal_title：Clinical neuropharmacology

authors： Sato Y,Shinozaki M,Okayasu H,Yasui-Furukori N,Shimoda K

更新日期：2020-05-01 00:00:00

abstract：OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

journal_title：Clinical neuropharmacology

authors： Elble RJ,Lyons KE,Pahwa R

更新日期：2007-11-01 00:00:00

abstract：OBJECTIVE:To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom. METHODS:We retrospectively reviewed the charts of 518 patients treated with TBZ to determine the frequency of depression and other adverse events. Char...

journal_title：Clinical neuropharmacology

authors： Kenney C,Hunter C,Mejia N,Jankovic J

更新日期：2006-09-01 00:00:00

abstract：:Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

journal_title：Clinical neuropharmacology

authors： Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

更新日期：2003-09-01 00:00:00

abstract：OBJECTIVE:Psychogenic polydipsia occurs frequently in patients with chronic psychiatric illness and is often unmanageable. We herein report 5 patients in whom acetazolamide was trialed for this symptom. METHODS:We encountered a case in which polydipsia improved with incidental administration of acetazolamide. We then ...

journal_title：Clinical neuropharmacology

authors： Takagi S,Watanabe Y,Imaoka T,Sakata M,Watanabe M

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVES:The high incidence of fibrotic cardiac valvulopathies reported in association with the 8beta-ergoline dopamine (DA) agonist, pergolide, and also case reports for cabergoline and bromocriptine have made it necessary to review the theoretical basis and actual findings in the case of another DA agonist, the 8al...

journal_title：Clinical neuropharmacology

authors： Hofmann C,Penner U,Dorow R,Pertz HH,Jähnichen S,Horowski R,Latté KP,Palla D,Schurad B

更新日期：2006-03-01 00:00:00

abstract：OBJECTIVES:A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The ...

journal_title：Clinical neuropharmacology

authors： Peng PJ,Ho PS,Tsai CK,Huang SY,Liang CS

更新日期：2016-11-01 00:00:00

abstract：:A 56 year-old woman who suffered from parkinsonism, oro-lingual dyskinesia (OLD) and tardive akathisia (TA) due to sulpiride is reported. OLD and TA appeared after sulpiride withdrawal. The patient was successfully treated with tetrabenazine even a mild parkinsonism was present. TA seems to be related with an apparent...

journal_title：Clinical neuropharmacology

authors： López de Munain A,Poza JJ,Gorospe A,Arce A,Martí Massó JF

更新日期：1994-10-01 00:00:00

abstract：BACKGROUND AND PURPOSE:Treatment of chronic insomnia with nightly hypnotics is efficacious, but discontinuation is recommended after 1 month, less than the average disease duration. This study was undertaken to determine the efficacy of intermittent administration. PATIENTS AND METHODS:A double-blind study was carried...

journal_title：Clinical neuropharmacology

authors： Parrino L,Smerieri A,Giglia F,Milioli G,De Paolis F,Terzano MG

更新日期：2008-01-01 00:00:00

abstract：:Interferons are a set of cytokines that activate antiviral responses by the body's immune cells and have been a mainstay of treatment of hepatitis C. Well-known neuropsychiatric effects of interferons include depression, irritability, and impaired concentration. A condition reported rarely in association with this tre...

journal_title：Clinical neuropharmacology

authors： Wangensteen KJ,Krawitt EL,Hamill RW,Boyd JT

更新日期：2016-01-01 00:00:00

abstract：:Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

journal_title：Clinical neuropharmacology

authors： Rajput AH,Rozdilsky B,Rajput A,Ang L

更新日期：1990-12-01 00:00:00

abstract：:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

journal_title：Clinical neuropharmacology

authors： Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

更新日期：1988-02-01 00:00:00

abstract：:Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

journal_title：Clinical neuropharmacology

authors： Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

更新日期：2004-11-01 00:00:00

abstract：OBJECTIVES:Neurosyphilis, an infectious neuroinflammatory disorder, could cause diverse neuropsychiatric symptoms mimicking disorders of schizophrenia and dementia; hence, it is known as the "chameleon of psychiatry." Here, we present a subject with neurosyphilis with schizophrenic features and share the treatment outc...

journal_title：Clinical neuropharmacology

authors： Chen WC,Wang HY,Chen PA,Chen IC,Chen YC

更新日期：2019-07-01 00:00:00

abstract：:Clozapine often causes low-grade fever and less frequently spiking fever. We describe three cases of spiking fever that occurred in the first 3 weeks of clozapine therapy. A new set of side effects of clozapine is identified, which includes spiking fever, respiratory and gastrointestinal symptoms, and neutrophilia. Po...

journal_title：Clinical neuropharmacology

authors： Trémeau F,Clark SC,Printz D,Kegeles LS,Malaspina D

更新日期：1997-04-01 00:00:00

abstract：:To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

journal_title：Clinical neuropharmacology

authors： Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

更新日期：1993-02-01 00:00:00